Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hye-Been Yoo
Institution:
Daewoong Pharmaceutical (South Korea)
Observed institutions:
Yonsei University,
Daewoong Pharmaceutical (South Korea)
ORCID:
0009-0004-2234-4629
Observed ORCID:
0009-0004-2234-4629
OpenAlex ID:
A5091372793
EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer
2021
·
Hwa-Ryeon Kim
, Juhye Yim
, et al.
·
NAR Cancer
·
21
A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer
2023
·
Hye-Been Yoo
, Jin Woo Moon
, et al.
·
Gastroenterology
·
16
PDF
Current advances and future directions in targeting histone demethylases for cancer therapy
2025
·
June-Ha Shin
, Hye-Been Yoo
, et al.
·
Molecules and Cells
·
13
Abstract 7091: DWP216, a TEAD1/2 inhibitor, enhances efficacy of diverse KRAS inhibitors by reversing resistance mechanisms in RAS-dependent cancers
2026
·
Bora Yoo
, Ye Gi Han
, et al.
·
Cancer Research
Show more works
View as search
Works count:
4
Citation count:
50
H-index:
3
I10-index:
3
Year
Topic
Type
